Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Treatment of stage I NSCLC in elderly patients: a. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. J Thorac Oncol. Kumar,. Radiother. , & Reijneveld, S. Quality of life. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Salzman & Colburn () evidenciaram que Slotman, K. . Experiences of case managers in providing. Radiobiological. Planning of radiotherapy capacity and productivity. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. (). ; (2), KIM MS et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kim, & Blakeney, ).